Prescription medicine
Spinosad Brand names: Natroba
Spinosad (Natroba) is a prescription medicine with an FDA approval on record since 2011. No generic is listed; pharmacies paid $2.02 per mL (Spinosad 0.9% topical suspension) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the spinosad FDA label on DailyMed (effective March 4, 2026, Cipher Pharmaceuticals Inc.); the NDA 22408 record on Drugs@FDA; every spinosad label on DailyMed.
Highlights of the record
FDA label of March 4, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageNATROBA is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older.
Forms and strengths
- 9 mg/ml
Suspension.
On the market
- Earliest approval on file
- January 18, 2011 Natroba, Cipher; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 3 of which 0 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- November 25, 2033 Natroba suspension; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $2.02 per mL Spinosad 0.9% topical suspension
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 45 through July 30, 2026
What is spinosad used for?
From the label: indications and usageNATROBA is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. ( 1.1 ) NATROBA is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older. ( 1.2 ) 1.1 Head Lice Infestations NATROBA is indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. Adjunctive Measures for Head Lice Infestations NATROBA should be used in the context of an overall lice management program: Wash in hot water or dry-clean all recently worn clothing, hats, used bedding and towels. […]
FDA pharmacologic class: Pediculicide.
Source: FDA drug label (Natroba), Cipher Pharmaceuticals Inc., effective March 4, 2026 (SPL set 72cf38f4-9ef4-4b0e-b085-b02f399e2592), via openFDA; the full label on DailyMed
Is there a generic for spinosad (Natroba)?
No generic spinosad is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 1 patent for Natroba suspension, the last expiring on November 25, 2033. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2011 earliest approval on file
- 2033 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for spinosad (Natroba)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $2.02 per mL (Spinosad 0.9% topical suspension), up 7% from $1.89 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Spinosad 0.9% topical suspension (generic)
- Natroba 0.9% topical suspension (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Spinosad 0.9% topical suspension | Generic | $2.02 per mL | n/a | +7% |
| Natroba 0.9% topical suspension | Brand | $2.20 per mL | n/a | -0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for spinosad?
The FDA Adverse Event Reporting System holds 45 reports that list spinosad among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2 are coded as a death and 2 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other pediculicides
- the pharmacologic class, with prices and generics
- Spinosad side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other